



Fast Facts

Founders:	Tillman Gerngross Charles Hutchinson
Date Founded:	2000
Date Acquired:	2006
Acquired By:	Merck
Employees:	N/A
Headquarters:	Lebanon, NH
Revenue:	N/A
University:	Dartmouth College
Federal Funding Agency:	National Institutes of Health
Initial Research Funding:	Approx. \$1M

More than half of all drugs currently in development worldwide depend on the genetic engineering of living cells to produce specific recombinant proteins. GlycoFi engineers strains of yeast to perform controlled, reliable, specific glycosylation, producing proteins with improved therapeutic capabilities. The technology optimizes drug performance while improving manufacturing efficiency.

The Story Behind the Company

Dartmouth Professors Tillman Gerngross and Charles Hutchinson founded GlycoFi in 2000 after discovering a proprietary technology for turning yeast cells into therapeutic protein factories. Through their research, the professors achieved the complete humanization of the glycosylation pathway in the yeast *Pichia pastoris*. Gerngross credits much of his early work, which led to the discovery behind GlycoFi, to support from the National Institutes of Health.

GlycoFi was acquired by Merck for \$400M in 2006. At the time, it was reported to be the third-highest price paid for a private biotechnology firm. GlycoFi continues to operate today in laboratory space in Lebanon, NH with more than 60 employees.

Gerngross remains a faculty member at Dartmouth and also helps direct Dartmouth's office of Technology Innovation and Entrepreneurship. Hutchinson is an Emeritus faculty member of Dartmouth's Thayer School of Engineering.



Developing Treatment of Cancer and Infectious Disease

ImmuNext Inc.
16 Cavendish Court
Lebanon, NH 03766
<http://immunext.com/index.php>



Fast Facts

Founders:	Randolph Noelle
Date Founded:	2010
Employees:	5
Headquarters:	Lebanon, NH
Revenue:	N/A
University:	Dartmouth College
Federal Funding Agency:	National Institutes of Health
Initial Research Funding:	\$425,000

ImmuNext is dedicated to developing novel therapeutics that modulate the immune system to treat cancer and autoimmune diseases. The company is developing immune-based, protein-based therapeutics to treat patients with immune-related disorders, including autoimmunity, cancer, transplantation rejection and infectious disease. ImmuNext targets critical immuno-modulatory molecules that either promote or suppress immune responses to restore immune homeostasis and cure disease. Using both antibody-based therapeutics and novel recombinant fusion proteins, a spectrum of newly identified molecules are being targeted to achieve disease remission.

The Story Behind the Company

Dr. Randolph Noelle, ImmuNext founder and Chief Scientific Officer, is a professor in the Geisel School of Medicine at Dartmouth. His research has identified a number of immuno-modulatory targets and related drug candidates. The lead ImmuNext program is based on Dr. Noelle’s research on VISTA, a novel checkpoint regulator in the B7 family. VISTA was founded in Noelle’s lab and is one of the targets that was licensed from Dartmouth to ImmuNext to develop for therapeutic use in cancer and autoimmunity.